Free Trial

Adial Pharmaceuticals (ADIL) Competitors

Adial Pharmaceuticals logo
$0.51 +0.03 (+7.04%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$0.54 +0.03 (+4.86%)
As of 07/25/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADIL vs. LEXX, HOOK, NEUP, ERNA, SYBX, BFRG, MTVA, BCTX, LPTX, and TXMD

Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Lexaria Bioscience (LEXX), HOOKIPA Pharma (HOOK), Neuphoria Therapeutics (NEUP), Ernexa Therapeutics (ERNA), Synlogic (SYBX), Bullfrog AI (BFRG), MetaVia (MTVA), Briacell Therap (BCTX), Leap Therapeutics (LPTX), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry.

Adial Pharmaceuticals vs. Its Competitors

Lexaria Bioscience (NASDAQ:LEXX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.63 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Lexaria Bioscience Positive
Adial Pharmaceuticals Very Positive

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 4.3% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lexaria Bioscience currently has a consensus price target of $5.00, indicating a potential upside of 411.25%. Adial Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 1,456.42%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Lexaria Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexaria Bioscience
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Adial Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Adial Pharmaceuticals has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Lexaria Bioscience's return on equity of -157.22% beat Adial Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lexaria Bioscience-1,849.19% -157.22% -133.69%
Adial Pharmaceuticals N/A -218.88%-177.61%

Lexaria Bioscience has higher revenue and earnings than Adial Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$460K41.59-$5.80M-$0.67-1.46
Adial PharmaceuticalsN/AN/A-$13.20M-$1.46-0.35

Lexaria Bioscience has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Summary

Adial Pharmaceuticals beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADIL vs. The Competition

MetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$5.01M$136.79M$5.70B$9.50B
Dividend YieldN/A3.74%4.69%4.01%
P/E Ratio-0.353.7528.1020.06
Price / SalesN/A4,471.55428.7189.10
Price / CashN/A13.1936.2258.56
Price / Book0.8042.328.665.87
Net Income-$13.20M-$90.99M$3.25B$258.55M
7 Day Performance13.92%4.82%4.22%3.73%
1 Month Performance9.41%8.35%10.51%11.75%
1 Year Performance-51.05%195.88%34.40%18.02%

Adial Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADIL
Adial Pharmaceuticals
2.9178 of 5 stars
$0.51
+7.0%
$8.00
+1,456.4%
-56.1%$5.01MN/A-0.3520Positive News
Analyst Upgrade
LEXX
Lexaria Bioscience
2.2435 of 5 stars
$0.83
-5.3%
$5.00
+499.4%
-68.3%$14.65M$460K-1.417
HOOK
HOOKIPA Pharma
3.0625 of 5 stars
$1.20
+0.8%
$4.50
+275.0%
-85.4%$14.63M$43.95M-0.21160News Coverage
NEUP
Neuphoria Therapeutics
2.2034 of 5 stars
$7.70
+0.1%
$21.00
+172.7%
N/A$14.48M$15.66M0.00N/ANews Coverage
Positive News
Analyst Upgrade
ERNA
Ernexa Therapeutics
1.0934 of 5 stars
$1.96
+0.5%
N/A-92.8%$14.44M$535K-0.2410Positive News
Gap Up
SYBX
Synlogic
1.3119 of 5 stars
$1.23
+1.2%
N/A-5.4%$14.33M$10K-0.4980Positive News
Gap Up
BFRG
Bullfrog AI
0.4159 of 5 stars
$1.51
flat
N/A-52.8%$14.22M$60K-1.864
MTVA
MetaVia
2.2605 of 5 stars
$0.71
-1.1%
$7.50
+956.5%
N/A$13.91MN/A0.008
BCTX
Briacell Therap
2.298 of 5 stars
$2.02
flat
$32.00
+1,484.2%
-93.1%$13.69MN/A-0.248Positive News
LPTX
Leap Therapeutics
2.1055 of 5 stars
$0.33
+0.1%
$3.38
+922.4%
-83.4%$13.68MN/A-0.1940Positive News
Gap Down
TXMD
TherapeuticsMD
0.4354 of 5 stars
$1.17
-0.8%
N/A-33.5%$13.54M$1.76M0.00420Positive News

Related Companies and Tools


This page (NASDAQ:ADIL) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners